Patents by Inventor Karim A. Benhadji

Karim A. Benhadji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION
    Publication number: 20240122937
    Abstract: A method of treating a subject with a cancerous tumor exhibiting an inactivating mutation in the PTEN gene including administering to the subject trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenylcyclobutanol or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: April 18, 2024
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Karim BENHADJI, Osamu TAKAHASHI
  • Targeted treatment of leiomyosarcoma
    Patent number: 10555951
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: February 11, 2020
    Assignee: ELI LILLY AND COMPANY
    Inventors: Karim A. Benhadji, Christophe Massard, Jean-Charles Soria
  • TARGETED TREATMENT OF LEIOMYOSARCOMA
    Publication number: 20180104254
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 19, 2018
    Inventors: Karim A. Benhadji, Christophe Massard, Jean-Charles Soria